Personal CFO Solutions LLC Has $1.40 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Personal CFO Solutions LLC lifted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 1.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 21,298 shares of the company’s stock after purchasing an additional 210 shares during the quarter. Personal CFO Solutions LLC’s holdings in AstraZeneca were worth $1,395,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Capital Performance Advisors LLP acquired a new position in AstraZeneca during the 3rd quarter worth approximately $28,000. Ashton Thomas Securities LLC acquired a new position in AstraZeneca during the 3rd quarter worth approximately $45,000. Albion Financial Group UT boosted its position in AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after acquiring an additional 248 shares during the last quarter. Hollencrest Capital Management boosted its position in AstraZeneca by 38.4% during the 3rd quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after acquiring an additional 192 shares during the last quarter. Finally, Versant Capital Management Inc boosted its position in AstraZeneca by 2,618.5% during the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock worth $48,000 after acquiring an additional 707 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Trading Up 0.0 %

Shares of AstraZeneca stock opened at $77.50 on Friday. AstraZeneca PLC has a 12-month low of $62.75 and a 12-month high of $87.68. The business’s 50 day moving average is $70.83 and its 200-day moving average is $72.74. The company has a quick ratio of 0.74, a current ratio of 0.93 and a debt-to-equity ratio of 0.65. The stock has a market cap of $240.34 billion, a P/E ratio of 34.29, a P/E/G ratio of 1.42 and a beta of 0.41.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. Equities research analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Monday, March 24th. Shareholders of record on Friday, February 21st will be issued a $1.03 dividend. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.49. This represents a yield of 2%. The ex-dividend date of this dividend is Friday, February 21st. AstraZeneca’s dividend payout ratio is currently 91.15%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AZN. UBS Group upgraded AstraZeneca from a “neutral” rating to a “buy” rating in a research note on Thursday, February 13th. Morgan Stanley began coverage on AstraZeneca in a research note on Wednesday, February 12th. They set an “overweight” rating on the stock. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Buy” and an average target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.